<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01490567</url>
  </required_header>
  <id_info>
    <org_study_id>NSFC30900485</org_study_id>
    <secondary_id>201002003</secondary_id>
    <nct_id>NCT01490567</nct_id>
  </id_info>
  <brief_title>A Double-blind, Placebo-controlled Trial of Donepezil Adjunctive Treatment for Cognitive Impairment in Schizophrenia</brief_title>
  <official_title>Donepezil Adjunctive Treatment for Cognitive Impairment in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central South University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study was to study the effects of donepezil on cognition in patients
      with schizophrenia. The investigators conducted a 12-week, double-blind, placebo-controlled
      trial of donepezil as adjunctive treatment to antipsychotic drugs on patients with
      schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators conducted a 12-week, double-blind, placebo-controlled trial of donepezil as
      adjunctive treatment to antipsychotic drugs on patients with schizophrenia.The trial will be
      complete in 2012.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in the Composite Score From the Cognition Assessment Battery After 12 Weeks of Treatment</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Cognition Assessment scores After 12 Weeks of Treatment</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Impaired Cognition</condition>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be given with a dose of 5mg/day placebo. All drugs will be administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>donepezil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be given with a dose of 5 mg/day donepezil. All drugs will be administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil</intervention_name>
    <description>5 mg/day</description>
    <arm_group_label>donepezil</arm_group_label>
    <other_name>Donepezil hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo 5mg/d</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM-IV diagnosis of schizophrenia as determined by the Structured Clinical Interview
             for DSM-IV Axis I Disorders-Clinician Version;

          -  Between 18 and 40 years of age;

          -  Duration of the illness must be longer than 2 year;

          -  Patient's current antipsychotic medication regimen must be stable;

          -  Must be in a stable living arrangement;

        Exclusion Criteria:

          -  Patient has mental retardation or severe organic brain syndromes;

          -  Treatment with Electroconvulsive Therapy (ECT) within 6 months prior to screening;

          -  Has suicidal attempts or ideation or violent behavior within the last 12 months;

          -  Patient has a history of alcohol/drug dependence;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaofeng Guo, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>the Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaofeng Guo, Doctor</last_name>
      <phone>86-731-85554052</phone>
      <email>gxfd@sina.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2011</study_first_submitted>
  <study_first_submitted_qc>December 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2011</study_first_posted>
  <last_update_submitted>December 9, 2011</last_update_submitted>
  <last_update_submitted_qc>December 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central South University</investigator_affiliation>
    <investigator_full_name>xiaofeng Guo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Impaired Cognition Schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

